Clinical Trial Update: A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC [Phase 3]

View source ↗

Summary

Phase 3 multicenter trial evaluating APF530 (granisetron) given subcutaneously to prevent chemotherapy-induced nausea and vomiting in patients receiving highly …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• APF530 (granisetron extended-release formulation)

Snippet

Sponsor: Heron Therapeutics | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 3 | Status: COMPLETED | Results posted: 2016-12-28